Suxamethonium
Generic name
Suxamethonium
Brand name
ATC Code
M03AB01
- Dosages
- Side effects in children
- Warnings & precautions in children
- Contra-indications in children
-
Interactions - PK
- Renal impairment
- References
Pharmacokinetics in children
No information
dose recommendation of formulary compared to licensed use (on-label versus off-label)
No information is present at this moment.
Available formulations
No information is present at this moment.
Dosages
| Relaxation of the skeletal muscles |
|---|
|
Renal impaiment in children > 3 months
GFR ≥10 ml/min/1.73m2: Dose adjustment not required.
GFR <10 ml/min/1.73m2: A general recommendation on dose adjustment cannot be provided.
a single dose may be administered provided there is no hyperkalemia. Do not give multiple or high doses as this may cause a clinically significant increase in serum potassium. (SmPC)
The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here
Side effects in children
Very common (>10%): Myoglobinaemia, arrhythmias (bradycardia, AV node arrhythmias, ectopic heartbeats)
Rare (0.01-0.1 %): Myoglobinuria and subsequent renal failure or acute heart failure (especially in children and adolescents treated with suxamethonium chloride and halothane due to leakage of potassium, creatinine phosphokinase and myoglobin from the muscle cell after administration of Lysthenon 2%)
Very rare (<0.01%): Cardiac arrest (especially in children with unrecognised skeletal muscle diseases such as Duchenne muscular dystrophy)
[GER_SmPC Lysthenon® 2 %, Injektionslösung (6428407.01.00), Takeda GmbH, 01/2022]
The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here
Contra-indications
No information available on specific contra indications in children.
The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here
Warnings & precautions in children
Bradycardia is observed more frequently in children and with repeated administration of suxamethonium (in both children and adults). Prior treatment with intravenous atropine or glycopyrronium significantly reduces the incidence and severity of bradycardia. Intramuscular atropine is not effective. Nontreatable cases of cardiac arrest have been described in children in whom neuromuscular disease had not been previously diagnosed. Use extreme caution and monitor extra in infants and children receiving suxamethonium because of increased risk of application in previously undiagnosed muscular disorders or propensity for malignant hyperthermia previously unknown.
Interactions
The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here
MUSCLE RELAXANTS, PERIPHERALLY ACTING AGENTS
This pages provides a list of drugs from the same ATC class for comparison. This does not necessarily mean that these drugs are interchangeable.
| Other quaternary ammonium compounds | ||
|---|---|---|
| M03AC04 | ||
| M03AC11 | ||
| M03AC10 | ||
| M03AC01 | ||
| M03AC09 | ||
| M03AC03 | ||
| Other muscle relaxants, peripherally acting agents | ||
|---|---|---|
| M03AX01 | ||
References
- Ethypharm, SmPC Suxamethoniumchloride Ethypharm - 50 mg/ ml (RVG 123872) - 20-03-2020, www.geneesmiddeleninformatiebank.nl
- Takeda GmbH, SmPC Lysthenon® 2 %, Injektionslösung (6428407.01.00), 01/2022
Changes
Therapeutic Drug Monitoring
Overdose
